Objective To investigate the clinical value of Mycobacterium tuberculosis/nontuberculous mycobacteria(MTB/NTM)nucleic acid detection in cerebrospinal fluid for the diagnosis of tuberculous meningitis(TBM).Methods The clinical data of 120 pa-tients with TBM were collected.Patients were divided into two groups using a random number table method:TBM A group(n=67,cere-brospinal fluid routine,biochemical,Roche culture,tuberculous smear,MTB/NTM nucleic acid detection)and TBM B group(n=53,cerebrospinal fluid routine,biochemical,Roche culture,tuberculous smear,GeneXpert MTB/RIF detection),and another 18 cases of cerebrospinal fluid from patients with other central nervous system infections were collected as control group(C group,cerebrospinal fluid routine,biochemical,Roche culture,tuberculous smear,MTB/NTM nucleic acid,GeneXpert MTB/RIF detection.Results The posi-tive rates of Roche culture,tuberculosis smear and MTB/NTM nucleic acid detection of cerebrospinal fluid in TBM A group were 13.43％(9/67),10.45％(7/67)and 46.27％(31/67),respectively.The positive rates of Roche culture,tuberculosis smear and GeneXpert MTB/RIF detection of cerebrospinal fluid in TBM B group were 15.09％(8/53),11.32％(6/53)and 47.17％(25/53),respective-ly.Among the cerebrospinal fluid GeneXpert MTB/RIF positive cases,lifampin resistance gene was positive in 2 patients.In the C group,patients had negative result in Roche culture,tuberculous smear,MTB/NTM nucleic acid detection and GeneXpert MTB/RIF detection.Conclusion MTB/NTM nucleic acid detection and GeneXpert MTB/RIF detection are useful in diagnosing TBM at early stage.MTB/NTM nucleic acid detection more economical than GeneXpert MTB/RIF detection,and can identify non-tuberculous mycobacteria(NTM),and timely reduce the misdiagnosis of NTM disease,which is worthy of clinical promotion.

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.
.

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Improving outcomes and obtaining long-term survival are the most urgent needs of patients with advanced NSCLC. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs), especially targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), have made a breakthrough in the treatment of NSCLC, beneficial to patients' survival and changed the treatment pattern for NSCLC. It shows more and more important role in the treatment of NSCLC. Led by NSCLC expert committee of Chinese society of clinical oncology (CSCO), relevant experts in this field were organized. On the basis of referring to domestic and foreign literature, systematically evaluating the results of Chinese and foreign clinical trials, and combining the experiences of the experts, the experts group reached an agreement to develop this consensus. It will guide domestic counterparts for better application of ICIs to treat NSCLC.

Objective:To investigate the extracellular signal-regulated kinase 5 (ERK5) and matrix metallo proteinase-9 (MMP-9) expres-sion levels in osteosarcoma tissues and their clinical significance. Methods:The ERK5 and MMP-9 expression levels in 71 specimens of osteosarcoma tissue and 40 specimens of normal bone tissue were detected by immunohistochemistry. The relationship between ERK5 and MMP-9 expression levels, their clinical characteristics, and prognosis of patients with osteosarcoma were analyzed. Results:The positive expression of ERK5 and MMP-9 in osteosarcoma tissues was 85.9%(61/71) and 74.65%(53/71), respectively, which were significantly higher than those in normal bone tissues at 12.5%(5/40) and 10.0%(4/40) (all P<0.05). The positive expression of ERK5 and MMP-9 was associated with Enneking stage and metastasis (all P<0.05). Kaplan-Meier analysis showed that the survival duration of patients with positive ERK5 and MMP-9 expression levels was shorter than those of the patients in the negative expression groups (all P<0.05). Univariate analysis of COX proportional hazards regression model revealed that tumor size, Enneking stage, metastasis, and positive ERK5 and MMP-9 expression levels are relevant to the overall survival of patients with osteosarcoma (all P<0.05). Multi-variate analysis of COX proportional hazards regression model confirmed that Enneking stage, metastasis, and positive ERK5 and MMP-9 expression levels can act as independent prognostic factors for osteosarcoma patients (all P<0.05). Conclusion:The ERK5 and MMP-9 expression levels are high in osteosarcoma tissues and are related to the clinical characteristics and prognosis of patients with osteo-sarcoma. Thus, ERK5 and MMP-9 expression levels may play important roles in osteosarcoma development and progression.